Clinical Trials Logo
  1. Home
  2. Head and Neck Cancer
  3. NCT06152055
  4. Details
NCT06152055 Clinical Trial

Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal

Head and Neck Cancer Clinical Trial

Official title:
Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal - A Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06152055
Other study ID # 245
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date April 30, 2023

Study information
Verified date November 2023
Source Tribhuvan University, Nepal
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a observational study conducted at the department of Ear ,Nose and Throat -Head and Neck Surgery (ENT-HNS) of Shree Birendra Hospital ,a tertiary health care centre of Nepal. Head and Neck cancers are the sixth most common cancer in the world. Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023.The main aim of the study was to know about the common cancers of head and neck region and their distribution according to the site. Also to know the stage of the presentation with treatment modalities in the tertiary health care centre of Nepal.

Description:

This is a retrospective study to know the prevalence of Head and Neck Cancer at the department of ENT- Head and Neck Surgery of Shree Birendra Hospital ,a tertiary health care centre of Nepal .Head and neck cancers are malignant neoplasms that develops in oral cavity, nasal cavities, paranasal sinuses,nasopharynx, oropharynx, hypopharynx, ear, scalp, salivary gland and neck,Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023. Data considered of demographic details of age, sex, diagnosis, subsite specific Head and Neck Cancers, treatment modality and histopathology. The data was analyzed using Stastical Package for Social Sciences (SPSS) version 22. Pearson's chi-square test was applied and p value <0.05 was considered statistically significant.

Recruitment information / eligibility
Status Completed
Enrollment 76
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 17 Years to 84 Years
Eligibility Inclusion Criteria: - All histologically proven cases of head and neck region. Exclusion Criteria: - Patient's record with incomplete data.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Nepal Shree Birendra Hospital Kathmandu

Sponsors (1)
Lead Sponsor Collaborator
Tribhuvan University, Nepal

Country where clinical trial is conducted

Nepal, 

References & Publications (1)

Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8. doi: 10.1586/14737140.6.7.1111. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Age - wise Distribution of Head and Neck Cancers (HNCs) Age - wise Distribution of Head and Neck Cancer 1 year
Primary : Distribution of HNCs according to subsite Distribution of Head and Neck Cancers according to the subsite 1 year
Primary Histopathology of HNCs Histopathology of Head and Neck Cancer 1 year
Primary Tumor, Nodes, Metastasis (TNM) staging of HNC Staging at presentation of Head and Neck Cancer 1 year
Primary Treatment provided to HNC patients Treatment Modalities of Head and Neck Cancer 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Recruiting NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2
Active, not recruiting NCT03688646 - Efficacy of ONS Supplementation in HNC Outpatient Under Treatment N/A